Brief: Hls Therapeutics Announces Fiscal 2023 Financial Results

HLS Therapeutics

14/03/2024 11:59

March 14 (Reuters) - HLS Therapeutics Inc  HLS.TO :
    * HLS THERAPEUTICS ANNOUNCES FISCAL 2023 FINANCIAL RESULTS
    * HLS IS TARGETING 2024 CONSOLIDATED REVENUE OF $63.5-66.5
MILLION, OR 1-5% GROWTH
    * LOOKING AHEAD TO 2025 AND BEYOND, WE EXPECT CONSOLIDATED
REVENUE
AND ADJUSTED EBITDA GROWTH TO IMPROVE CONSIDERABLY
    * AMENDED TERMS OF ITS CREDIT AGREEMENT TO MODIFY CERTAIN
COVENANT
RATIOS
    * UNDER AMENDED AGREEMENT, COMPANY'S REVOLVING FACILITY HAS
BEEN
REDUCED TO $25 MILLION FROM $30 MILLION

Source text for Eikon:  ID:nCNWmvrMfa 
Further company coverage:  HLS.TO 

 ((Reuters.Briefs@thomsonreuters.com;))